Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline
SS Chang, SA Boorjian, R Chou, PE Clark… - The Journal of …, 2016 - auajournals.org
Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …
Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group
AM Kamat, RJ Sylvester, A Böhle, J Palou… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To provide recommendations on appropriate clinical trial designs in non–muscle-
invasive bladder cancer (NMIBC) based on current literature and expert consensus of the …
invasive bladder cancer (NMIBC) based on current literature and expert consensus of the …
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm …
AV Balar, AM Kamat, GS Kulkarni, EM Uchio… - The Lancet …, 2021 - thelancet.com
Background Standard treatment for high-risk non-muscle-invasive bladder cancer is
transurethral resection of bladder tumour followed by intravesical BCG immunotherapy …
transurethral resection of bladder tumour followed by intravesical BCG immunotherapy …
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
SA Boorjian, M Alemozaffar, BR Konety… - The Lancet …, 2021 - thelancet.com
Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder
cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient …
cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient …
Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer
Purpose: Rescue intravesical therapies for patients with bacillus Calmette-Guérin failure
nonmuscle invasive bladder cancer remain a critical focus of ongoing research. Sequential …
nonmuscle invasive bladder cancer remain a critical focus of ongoing research. Sequential …
IL-15 superagonist NAI in BCG-unresponsive non–muscle-invasive bladder cancer
K Chamie, SS Chang, E Kramolowsky… - NEJM …, 2022 - evidence.nejm.org
Abstract Background Patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–
muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell …
muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell …
Phase 2 trial of atezolizumab in bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer: SWOG S1605
PC Black, CM Tangen, P Singh, DJ McConkey… - European urology, 2023 - Elsevier
Background Although radical cystectomy (RC) is the standard of care for patients with
bacillus Calmette-Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder …
bacillus Calmette-Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder …
Intravesical rAd–IFNα/Syn3 for patients with high-grade, Bacillus Calmette-Guerin–refractory or relapsed non–muscle-invasive bladder cancer: a phase II randomized …
Purpose Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are
either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease …
either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease …
International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Guérin–exposed high-risk non–muscle-invasive …
Context A large proportion of patients with non–muscle-invasive bladder cancer (NMIBC) fall
in the gap between bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive disease …
in the gap between bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive disease …
Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non …
Background There is no effective intravesical second-line therapy for non–muscle-invasive
bladder cancer (NMIBC) when bacillus Calmette-Guérin (BCG) fails. Objective To compare …
bladder cancer (NMIBC) when bacillus Calmette-Guérin (BCG) fails. Objective To compare …